3KNX
HCV NS3 protease domain with P1-P3 macrocyclic ketoamide inhibitor
Summary for 3KNX
| Entry DOI | 10.2210/pdb3knx/pdb |
| Related | 3EYD |
| Descriptor | HCV NS3 Protease, HCV NS4a peptide, ZINC ION, ... (6 entities in total) |
| Functional Keywords | hepatitis c virus, ns3 protease domain, serine protease, macrocyclic ketoamide inhibitor, atp-binding, envelope protein, helicase, hydrolase, membrane, nucleotide-binding, rna replication, transmembrane, viral protein |
| Biological source | Hepatitis C virus subtype 1a More |
| Total number of polymer chains | 4 |
| Total formula weight | 48192.44 |
| Authors | Venkatraman, S.,Velazquez, F.,Wu, W.,Blackman, M.,Chen, K.X.,Bogen, S.,Nair, L.,Tong, X.,Chase, R.,Hart, A.,Agrawal, S.,Pichardo, J.,Prongay, A.,Cheng, K.-C.,Girijavallabhan, V.,Piwinski, J.,Shih, N.-Y.,Njoroge, F.G. (deposition date: 2009-11-12, release date: 2010-10-27, Last modification date: 2024-04-03) |
| Primary citation | Venkatraman, S.,Velazquez, F.,Wu, W.,Blackman, M.,Chen, K.X.,Bogen, S.,Nair, L.,Tong, X.,Chase, R.,Hart, A.,Agrawal, S.,Pichardo, J.,Prongay, A.,Cheng, K.C.,Girijavallabhan, V.,Piwinski, J.,Shih, N.Y.,Njoroge, F.G. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J.Med.Chem., 52:336-346, 2009 Cited by PubMed Abstract: Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, and affects more than 200 million people worldwide. Although combination therapy of interferon-alpha and ribavirin is reasonably successful in treating majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of a series of ketoamide derived P(1)-P(3) macrocyclic inhibitors that are more potent than the first generation clinical candidate, boceprevir (1, Sch 503034), is discussed. The optimization of these macrocyclic inhibitors identified a P(3) imide capped analogue 52 that was 20 times more potent than 1 and demonstrated good oral pharmacokinetics in rats. X-ray structure of 52 bound to NS3 protease and biological data are also discussed. PubMed: 19102654DOI: 10.1021/jm800940u PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.65 Å) |
Structure validation
Download full validation report
